Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease

Medium confidence53

The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults

First seen 1h ago · latest update 1h ago · India · science

Indian mainstream 1
Indian independent 0
International 0
Official 0

Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver diseaseHindustan Times · 1h ago ↗Owned by: HT Media (Bhartia family / Birla group)

Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease

Coverage (1)